ReviewCellular immunology2016
PI3K signaling in Leishmania infections.
Review in Cellular immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Linsitinib: a tyrosine kinase inhibitor with dual host-parasite targeting potential against leishmaniasis.Folia microbiologica · 2026Article
- Whole genome sequencing reveals genomic diversity and evidence of hybridization in MoroccanFrontiers in cellular and infection microbiology · 2026Article
- PI3K/AKT signaling in parasites and parasite diseases: Role and therapeutic potential.Virulence · 2025Review
- Transcriptome profiling of L. infantum-infected human macrophages reveals sex-specific type I interferon induction.PLoS pathogens · 2025Article
- Progress in antileishmanial drugs: Mechanisms, challenges, and prospects.PLoS neglected tropical diseases · 2025Review
- Can letrozole be repurposed for the treatment of visceral leishmaniasis?Antimicrobial agents and chemotherapy · 2024Article
- Non-Vesicular Lipid Transport Machinery inInternational journal of molecular sciences · 2023Review
- Transcriptomic Profile of Canine DH82 Macrophages Infected byInternational journal of molecular sciences · 2022Article
- Profilin is involved in G1 to S phase progression and mitotic spindle orientation during Leishmania donovani cell division cycle.PloS one · 2022Article
- Effects of Visceralising Leishmania on the Spleen, Liver, and Bone Marrow: A Pathophysiological Perspective.Microorganisms · 2021Review
- Transcriptional Studies onFrontiers in cellular and infection microbiology · 2021Review
- Detection and characterization of an albumin-like protein in Leishmania donovani.Parasitology research · 2019Article
- Glycoconjugates of Gram-negative bacteria and parasitic protozoa - are they similar in orchestrating the innate immune response?Innate immunity · 2019Review
- Leishmania parasitophorous vacuole membranes display phosphoinositides that create conditions for continuous Akt activation and a target for miltefosine in Leishmania infections.Cellular microbiology · 2018Article
- Countervailing, time-dependent effects on host autophagy promotes intracellular survival ofThe Journal of biological chemistry · 2018Article
- Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania.PloS one · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
PI3K signaling plays a role in the host response to Leishmania infections. At the cellular level PI3K signaling is engaged by the parasite to control several cellular processes, which ensures parasite persistence. At the systemic level, there is evidence that recruitment of regulatory cells into lesions is impaired in the absence of robust PI3K signaling. In this mini-review the more recent studies that investigated the roles of PI3K signaling in Leishmania infections are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.